General Information of Drug (ID: DMWJXFO)

Drug Name
Mezagitamab Drug Info
Synonyms TAK-079
Indication
Disease Entry ICD 11 Status REF
Myasthenia gravis 8C6Y Phase 2 [1]
Primary immune thrombocytopenia 3B64.10 Phase 2 [2]
IgA nephropathy MF8Y Phase 1 [3]
Cross-matching ID
TTD Drug ID
DMWJXFO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Daratumumab DMKCIUZ Multiple myeloma 2A83 Approved [5]
CD38 and BCMA CAR-T Cells DMFZS8A Multiple myeloma 2A83 Phase 1/2 [6]
4SCAR19 and 4SCAR38 DMZKFU7 B-cell lymphoma 2A86 Phase 1/2 [7]
ISB 1342 DMG107N Multiple myeloma 2A83 Phase 1/2 [8]
Anti-CD38 CAR-T cells DMTVXBY Multiple myeloma 2A83 Phase 1/2 [9]
CD38 CAR T cells DMPS3I6 Multiple myeloma 2A83 Phase 1/2 [10]
CD38 CAR-T Cell DM0USBX Acute lymphoblastic leukaemia 2A85 Phase 1/2 [11]
SAR-650984 DMD20YH Haematological malignancy 2B33.Y Phase 1/2 [12]
MOR-202 DMR8AHJ Multiple myeloma 2A83 Phase 1/2 [13]
Anti-CD38 CAR-T cells DMTVXBY Multiple myeloma 2A83 Phase 1/2 [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclic ADP-ribose hydrolase 1 (CD38) TTPURFN CD38_HUMAN Not Available [4]

References

1 ClinicalTrials.gov (NCT04159805) A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04278924) A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia. U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT05174221) A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy. U.S.National Institutes of Health.
4 Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. Br J Clin Pharmacol. 2020 Jul;86(7):1314-1325.
5 Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19.
6 ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
7 ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
8 Clinical pipeline report, company report or official report of Ichnos Sciences.
9 ClinicalTrials.gov (NCT03464916) Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
10 ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
11 ClinicalTrials.gov (NCT03754764) A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy
12 Clinical pipeline report, company report or official report of Sanofi-Aventis.
13 Clinical pipeline report, company report or official report of MorphoSys.
14 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies